{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:06:09Z","timestamp":1772755569072,"version":"3.50.1"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by genetic abnormalities, infections, autoimmune diseases, drugs, and malignancies. Anti-C5 monoclonal antibody eculizumab is the mainstay of treatment of aHUS caused by the genetic defects of the alternative complement pathway. However, the utility of eculizumab in non-genetic forms of aHUS and the timing of treatment discontinuation remain controversial. Here, we report successful short-term eculizumab use in two young adult patients with aHUS due to rare infectious and autoimmune etiologies: Lemierre's syndrome and post-infectious glomerulonephritis, respectively. Eculizumab was rapidly discontinued in both patients with no aHUS recurrence during long-term follow-up. Considering its favorable safety profile with appropriate meningococcal prophylaxis, eculizumab can be considered as a treatment option for non-genetic aHUS.<\/jats:p>","DOI":"10.3389\/fmed.2023.1167806","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:07:27Z","timestamp":1683112047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis"],"prefix":"10.3389","volume":"10","author":[{"given":"Sanober","family":"Sadiq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatoly","family":"Urisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"Cil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/S0140-6736(22)01202-8","article-title":"Haemolytic uraemic syndrome","volume":"400","author":"Walsh","year":"2022","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40272-022-00555-6","article-title":"Pharmacological management of atypical hemolytic uremic syndrome in pediatric patients: current and future","volume":"25","author":"Gurevich","year":"2023","journal-title":"Paediatr Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00467-022-05694-z","article-title":"HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl","volume":"38","author":"Galvez","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e9358","DOI":"10.1097\/MD.0000000000009358","article-title":"Efficacy of eculizumab in an adult patient with HIV-associated hemolytic uremic syndrome: a case report","volume":"96","author":"Freist","year":"2017","journal-title":"Medicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e60352","DOI":"10.1371\/journal.pone.0060352","article-title":"Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32","volume":"8","author":"Holmes","year":"2013","journal-title":"PLoS ONE"},{"key":"B7","doi-asserted-by":"publisher","first-page":"E22","DOI":"10.1053\/ajkd.2001.22099","article-title":"Hemolytic uremic syndrome in an adolescent with Fusobacterium necrophorum bacteremia","volume":"37","author":"Chand","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00467-010-1554-6","article-title":"Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis","volume":"26","author":"Eison","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/ckj\/sfv119","article-title":"Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: to treat or not to treat with eculizumab?","volume":"9","author":"Kakajiwala","year":"2016","journal-title":"Clin Kidney J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s004310000684","article-title":"Simultaneous occurrence of the haemolytic uraemic syndrome and acute post-infectious glomerulonephritis","volume":"160","author":"Laube","year":"2001","journal-title":"Eur J Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1136\/postgradmedj-2012-131416","article-title":"Pulmonary-renal syndrome: a life threatening but treatable condition","volume":"89","author":"West","year":"2013","journal-title":"Postgrad Med J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.330","article-title":"Interpretation of genetic variants of uncertain significance in atypical hemolytic uremic syndrome","author":"Kavanagh","year":"2012","journal-title":"Kidney Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04774-2","article-title":"The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab","author":"Tanaka","year":"2021","journal-title":"Pediatr Nephrol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1167806\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:07:29Z","timestamp":1683112049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1167806\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":14,"alternative-id":["10.3389\/fmed.2023.1167806"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1167806","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"article-number":"1167806"}}